EVAXION A/S (EVAX) Stock Fundamental Analysis
USA - NASDAQ:EVAX - US29970R3030 - ADR
2.945 USD
+0.06 (+2.26%)
EVAX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 541 industry peers in the Biotechnology industry. Both the profitability and financial health of EVAX have multiple concerns. EVAX is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year EVAX has reported negative net income.
EVAX had a negative operating cash flow in the past year.
In the past 5 years EVAX always reported negative net income.
EVAX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
EVAX's Return On Assets of -53.34% is in line compared to the rest of the industry. EVAX outperforms 48.24% of its industry peers.
EVAX has a Return On Equity of -192.34%. This is in the lower half of the industry: EVAX underperforms 66.73% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -53.34% | ||
| ROE | -192.34% | ||
| ROIC | N/A |
ROA(3y)-120.5%
ROA(5y)-109.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for EVAX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
EVAX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, EVAX has more shares outstanding
Compared to 5 years ago, EVAX has less shares outstanding
The debt/assets ratio for EVAX has been reduced compared to a year ago.
2.2 Solvency
EVAX has an Altman-Z score of -0.90. This is a bad value and indicates that EVAX is not financially healthy and even has some risk of bankruptcy.
EVAX's Altman-Z score of -0.90 is in line compared to the rest of the industry. EVAX outperforms 58.04% of its industry peers.
EVAX has a Debt/Equity ratio of 1.73. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 1.73, EVAX is doing worse than 79.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.73 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.9 |
ROIC/WACCN/A
WACC5.14%
2.3 Liquidity
EVAX has a Current Ratio of 3.42. This indicates that EVAX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of EVAX (3.42) is worse than 60.07% of its industry peers.
EVAX has a Quick Ratio of 3.42. This indicates that EVAX is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of EVAX (3.42) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.42 | ||
| Quick Ratio | 3.42 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 76.02% over the past year.
Looking at the last year, EVAX shows a very strong growth in Revenue. The Revenue has grown by 1042.45%.
EPS 1Y (TTM)76.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.67%
Revenue 1Y (TTM)1042.45%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-75.97%
3.2 Future
EVAX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.29% yearly.
The Revenue is expected to grow by 61.85% on average over the next years. This is a very strong growth
EPS Next Y18.95%
EPS Next 2Y14.6%
EPS Next 3Y26.37%
EPS Next 5Y15.29%
Revenue Next Year-100%
Revenue Next 2Y0.95%
Revenue Next 3Y59.75%
Revenue Next 5Y61.85%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for EVAX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EVAX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
EVAX's earnings are expected to grow with 26.37% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.6%
EPS Next 3Y26.37%
5. Dividend
5.1 Amount
No dividends for EVAX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:EVAX (9/12/2025, 8:00:02 PM)
2.945
+0.06 (+2.26%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners2.16%
Inst Owner Change-15.19%
Ins Owners0.68%
Ins Owner ChangeN/A
Market Cap18.60M
Analysts82.5
Price Target10.2 (246.35%)
Short Float %2.58%
Short Ratio1.23
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)60.81%
Min EPS beat(2)24.59%
Max EPS beat(2)97.03%
EPS beat(4)4
Avg EPS beat(4)54.87%
Min EPS beat(4)11.56%
Max EPS beat(4)97.03%
EPS beat(8)7
Avg EPS beat(8)54.84%
EPS beat(12)10
Avg EPS beat(12)37.39%
EPS beat(16)13
Avg EPS beat(16)31.2%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-73.68%
PT rev (3m)-68.67%
EPS NQ rev (1m)1.47%
EPS NQ rev (3m)-34%
EPS NY rev (1m)-1.83%
EPS NY rev (3m)12.4%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 5.86 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.99 | ||
| P/tB | 2.99 | ||
| EV/EBITDA | N/A |
EPS(TTM)-4.22
EYN/A
EPS(NY)-1.92
Fwd EYN/A
FCF(TTM)-1.85
FCFYN/A
OCF(TTM)-1.85
OCFYN/A
SpS0.5
BVpS0.99
TBVpS0.99
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -53.34% | ||
| ROE | -192.34% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-120.5%
ROA(5y)-109.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.14
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.73 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.42 | ||
| Quick Ratio | 3.42 | ||
| Altman-Z | -0.9 |
F-Score6
WACC5.14%
ROIC/WACCN/A
Cap/Depr(3y)21.76%
Cap/Depr(5y)127.17%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)76.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.67%
EPS Next Y18.95%
EPS Next 2Y14.6%
EPS Next 3Y26.37%
EPS Next 5Y15.29%
Revenue 1Y (TTM)1042.45%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-75.97%
Revenue Next Year-100%
Revenue Next 2Y0.95%
Revenue Next 3Y59.75%
Revenue Next 5Y61.85%
EBIT growth 1Y26.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year61.67%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y50.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y50.7%
OCF growth 3YN/A
OCF growth 5YN/A